CytomX Therapeutics (CTMX) Projected to Post Quarterly Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX) is expected to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $12.3880 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.04. CytomX Therapeutics had a negative net margin of 166.40% and a negative return on equity of 36.61%. The business had revenue of $10.26 million during the quarter, compared to analyst estimates of $4.68 million. On average, analysts expect CytomX Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

CytomX Therapeutics Stock Performance

NASDAQ:CTMX opened at $3.27 on Tuesday. The company’s 50-day simple moving average is $3.38 and its 200-day simple moving average is $4.30. CytomX Therapeutics has a fifty-two week low of $1.72 and a fifty-two week high of $8.21. The stock has a market capitalization of $557.37 million, a P/E ratio of -7.96 and a beta of 2.12.

Analyst Ratings Changes

A number of research firms recently commented on CTMX. HC Wainwright decreased their target price on shares of CytomX Therapeutics from $17.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Wall Street Zen raised shares of CytomX Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. Wolfe Research started coverage on CytomX Therapeutics in a research report on Tuesday, May 19th. They set an “outperform” rating and a $6.00 price target on the stock. Zacks Research upgraded CytomX Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of CytomX Therapeutics in a research report on Tuesday, June 16th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, CytomX Therapeutics presently has an average rating of “Buy” and a consensus price target of $12.10.

Institutional Trading of CytomX Therapeutics

Large investors have recently bought and sold shares of the stock. Orbimed Advisors LLC purchased a new position in shares of CytomX Therapeutics in the second quarter worth $19,208,000. Commodore Capital LP purchased a new stake in shares of CytomX Therapeutics during the second quarter valued at $17,462,000. Perceptive Advisors LLC acquired a new position in shares of CytomX Therapeutics in the 2nd quarter valued at $15,876,000. State Street Corp increased its position in shares of CytomX Therapeutics by 697.1% in the 4th quarter. State Street Corp now owns 5,140,931 shares of the biotechnology company’s stock valued at $21,900,000 after acquiring an additional 4,495,949 shares during the period. Finally, Balyasny Asset Management L.P. purchased a new position in CytomX Therapeutics in the 2nd quarter worth $6,505,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.